Sera Prognostics, Inc.
NASDAQ: SERA0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- NASDAQ Global Market
- Sector
- Healthcare
- Industry
- Medical - Diagnostics & Research
- CEO
- Zhenya Lindgardt
- Employees
- 63
- Headquarters
- Salt Lake City, United States
- IPO year
- 2021
- Market cap
- $68.7M
- Website
- https://seraprognostics.com
Loading SERA…
Loading profile data…Frequently asked questions about SERA
What does Sera Prognostics, Inc. (SERA) do?
Sera Prognostics, Inc. is a women's health diagnostics firm that focuses on creating, advancing, and bringing to market biomarker tests aimed at improving pregnancy results. Their primary product, the PreTRM test, is a blood-based biomarker assay specifically designed to predict the likelihood of spontaneous preterm birth in singleton pregnancie...
Where does SERA trade?
Sera Prognostics, Inc. (SERA) trades on the NASDAQ Global Market.
What sector is SERA in?
Sera Prognostics, Inc. (SERA) operates in the Healthcare sector, specifically in the Medical - Diagnostics & Research industry.
Who is the CEO of Sera Prognostics, Inc.?
Zhenya Lindgardt is the chief executive officer of Sera Prognostics, Inc. (SERA).
Where is Sera Prognostics, Inc. headquartered?
Sera Prognostics, Inc. is headquartered in United States.
Does SERA pay a dividend?
Sera Prognostics, Inc. (SERA) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did SERA go public?
Sera Prognostics, Inc. (SERA) completed its initial public offering in 2021.